Rodent models of Alzheimer’s disease: Critical analysis of current hypotheses and pathways for future research
Progress in Neurobiology. 2025-09-01; 252: 102821
DOI: 10.1016/j.pneurobio.2025.102821
Lire sur PubMed
https://www.bordeaux-neurocampus.fr/12416
Singhaarachchi PH(1), Antal P(2), Calon F(3), Culmsee C(4), Delpech JC(5),
Feldotto M(6), Geertsema J(7), Hoeksema EE(7), Korosi A(7), Layé S(5), McQualter
J(1), de Rooij SR(8), Rummel C(9), Slayo M(9), Sominsky L(10), Spencer SJ(11).
Author information:
(1)School of Health and Biomedical Sciences, RMIT University, Bundoora,
Melbourne, Victoria 3083, Australia.
(2)Department of Artificial Intelligence and Systems Engineering, Budapest
University of Technology and Economics, 1111, Hungary.
(3)Faculty of Pharmacy, Centre de Recherche du CHU de Québec-Laval University,
Quebec G1V 0A6, Canada; International Associated Laboratory
OptiNutriBrain-NutriNeuro, Bordeaux, France, F-33000 and INAF, Quebec, G1V 0A6,
Canada.
(4)Institute of Pharmacology and Clinical Pharmacy, Philipps University of
Marburg, Marburg D-35032, Germany; Center for Mind, Brain and Behavior-CMBB,
Giessen, D-35392, Marburg, D-35032, Germany.
(5)International Associated Laboratory OptiNutriBrain-NutriNeuro, Bordeaux,
France, F-33000 and INAF, Quebec, G1V 0A6, Canada; Université de Bordeaux,
INRAE, Bordeaux INP, NutriNeurO, UMR 1286, Bordeaux F-33000, France.
(6)Institute of Veterinary Physiology and Biochemistry, Justus Liebig University
Giessen, Giessen D-35392, Germany.
(7)Center for Neuroscience, Swammerdam Institute for Life Sciences, University
of Amsterdam, Amsterdam 1098 XH, the Netherlands.
(8)Department of Epidemiology and Data Science, Amsterdam University Medical
Centers, University of Amsterdam, 1105, the Netherlands.
(9)Center for Mind, Brain and Behavior-CMBB, Giessen, D-35392, Marburg, D-35032,
Germany; Institute of Veterinary Physiology and Biochemistry, Justus Liebig
University Giessen, Giessen D-35392, Germany.
(10)Barwon Health, Geelong, Victoria 3220, Australia; IMPACT – the Institute for
Mental and Physical Health and Clinical Translation, School of Medicine, Deakin
University, Geelong, Victoria 3217, Australia.
(11)School of Health and Biomedical Sciences, RMIT University, Bundoora,
Melbourne, Victoria 3083, Australia. Electronic address:
.
Alzheimer’s disease (AD) was first described over a century ago. However, the
mechanisms underlying the disease are not well understood to this day. This has
negatively impacted our ability to create animal models to design and test
targeted reliable treatments for the disease. Amyloid β plaque accumulation,
aggregation of neurofibrillary tangles, neuroinflammation, neurodegeneration,
and, of course, cognitive decline, are few of the many observed pathological
features associated with AD. However, there is a concern that the animal models
of AD that are based on these frameworks may not be accurately representing AD
in people. As such, the results from preclinical trials have not historically
translated well to the clinic. In this article, we review the current major
hypotheses to describe AD; we outline the major strengths and weaknesses of the
commonly used rodent models used to replicate features of these hypotheses; and
we provide a strategy for the field for future research.
Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.
DOI: 10.1016/j.pneurobio.2025.102821
PMID: 40886908 [Indexed for MEDLINE]
Conflict of interest statement: Declaration of Competing Interest The authors
have no conflicts of interest to declare.